Clinical outcome of gemcitabine/S-1 combination therapy for advanced pancreatic cancer.
Yamauchi
Junichi
J
Kanai
Masashi
M
Matsumoto
Shigemi
S
Nishimura
Takafumi
T
Yazumi
Shujiro
S
Kami
Kazuhiro
K
Kawaguchi
Yoshiya
Y
Yasuda
Hiroyasu
H
Kitano
Toshiyuki
T
Misawa
Akiko
A
Ishiguro
Hiroshi
H
Yoshikawa
Kiyotsugu
K
Yanagihara
Kazuhiro
K
Fukushima
Masanori
M
Doi
Ryuichiro
R
Chiba
Tsutomu
T
D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004338:Drug Combinations; D004359:Drug Therapy, Combination; D004361:Drug Tolerance; D006801:Humans; D010094:Oxonic Acid / Q000008:administration & dosage / Q000009:adverse effects; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000556:secondary; D012189:Retrospective Studies; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D016896:Treatment Outcome; D000093542:Gemcitabine
D000964:Antimetabolites, Antineoplastic; D004338:Drug Combinations; D003841:Deoxycytidine; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000093542:Gemcitabine